NCT01699061 - Effect of Tivantinib on the QTC Interval in Cancer Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

May 31, 2013

Conditions

Solid Tumors

Interventions

DRUG

Tivantinib

3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2

DRUG

Placebo

Placebo tablet administered with a meal twice a day on Day 1

Trial Locations (1)

START - South Texas Accelerated Research Therapeutics, LLC, San Antonio